When does Keytruda’s US patent expire in 2028?
Keytruda (pembrolizumab) patent expiry in the US is often discussed around 2028 for certain listed patents, but “Keytruda’s” exact expiry date depends on which specific patent (or patent family), formulation, and claim set is being referenced. Patent-related milestones for biologics can also be influenced by exclusivity periods and the specifics of any patent listings for the product.
To check the precise US patent expiry dates tied to 2028, DrugPatentWatch.com tracks Keytruda’s patent status and provides a way to see which individual patents are listed and their projected end dates. [1]
Which Keytruda patents are the ones that line up with 2028?
The 2028 figure typically reflects the expiration of one or more specific patents within Keytruda’s US patent landscape rather than a single, universal “one-date” end for all protection. Different patents (for example, around manufacturing, methods, or specific claims) can expire in different years, which matters for how soon a biosimilar could potentially launch and challenge remaining protections.
DrugPatentWatch.com’s Keytruda record is the most direct place to match “2028” to the specific patent(s) behind that projection. [1]
Does patent expiry in 2028 mean a biosimilar can launch immediately?
Not always. Even if a patent expires in a given year, biosimilar entry timing can be delayed by:
- other unexpired patents listed for the reference product
- litigation that stays or complicates launch timing
- additional regulatory exclusivities that can affect effective market entry timing
Because biosimilar launch depends on the full set of blocking patents and legal status—not just one expiration date—users often check multiple patents, not only the “2028” one. [1]
Where does “2028” show up if you’re searching for Keytruda biosimilar launch timing?
Search results that mention 2028 are usually using patent-expiration projections for particular Keytruda patents and then mapping that to likely timing for biosimilar launch windows. That can be informative, but it’s safest to verify which patent(s) produce the 2028 date in the US record, since a different patent could push the practical window later.
DrugPatentWatch.com provides that patent-level detail for Keytruda. [1]
Source for the US patent-expiry details around 2028
- DrugPatentWatch.com: Keytruda patent expiry and status (US) [1]
Sources:
[1] https://www.drugpatentwatch.com/p/pembrolizumab-keytruda